Lofted Custom Spirits Launches Alternating Proprietorship Program
4.8.2025 16:15:00 CEST | Business Wire | Press Release
Lofted Custom Spirits, the nation’s first and leading custom contract whiskey distiller, today announced the launch of a new Alternating Proprietorship program, allowing partners to take advantage of significantly reduced excise tax rates. Using their own DSP license and Lofted’s dedicated processing facility, craft brands can get the full benefit of Craft Beverage Modernization Act (CBMA) tax breaks and save an average $6 per proof gallon.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804995682/en/
Under current CBMA rules, only DSPs that perform processing activities beyond bottling—such as manufacturing, blending, filtering, or flavor addition—can claim the lower federal excise tax rate on up to 100,000 proof gallons annually. Lofted Custom Spirits’ Alternating Proprietorship opens the door to TTB-compliant tax savings not available through other Kentucky contract distillers.
“Lofted Custom Spirits built this program like we’ve built our business – on a foundation of true partnership, operational integrity, the utmost quality and strict compliance. This foundation of trust means that our clients can pour their energy into building great brands, not consumed by process and regulation,” said Mark Erwin, CEO of Lofted Spirits, the parent company of Lofted Custom Spirits, Bardstown Bourbon Company and Green River Distilling Co.
In a newly outfitted processing facility, the Lofted Custom Spirits will continue to provide hands-on support and labor under the client’s DSP license, ensuring seamless operation and continuity.
“We’ve worked closely with the TTB to bring this offering on board in a way that ensures operational effectiveness and full compliance with the industry regulations. As with every expansion we’ve made, we’ve created this program in the spirit of true partnership with the brands that trust us to keep their whiskey brand flowing,” said Erwin.
The Alternating Proprietorship is available now for both existing and new clients. For more information, visit LoftedSpirits.com.
ABOUT LOFTED SPIRITS
From bespoke bourbon production to boundary-pushing brands, Lofted Spirits is where tradition meets transformation. Expanding on the work started by Peter Loftin in 2016, and today the number one producer of Kentucky contract whiskey, Lofted Spirits pioneered a world-class, industry-shaking approach to custom contract distillation while developing some of the fastest growing brands in American Whiskey, Bardstown Bourbon and Green River. A unified entity, Lofted Spirits is built to lead the global whiskey industry, delivering exceptional experiences through innovation, trust and transformative industry impact while crafting some of the world’s most desired and awarded whiskies. Lofted Spirits joined the Pritzker Private Capital family of companies in 2022. Learn more at LoftedSpirits.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250804995682/en/
Contacts
Media Contact:
Holly Weyler
hweyler@loftedspirits.com
502.836.8715
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom